IPO registrations (S-1, F-1) · Registrants
bluebird bio, Inc.
- SEC CIK
- 1293971 · filings on EDGAR ↗
- Former names
- Genetix Pharmaceuticals Inc (2004–2010)
- Registration
- Form S-1, first filed 2013-05-14, last 2013-06-04; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2013-06-19; declared effective 2013-06-18
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 455 GRAND UNION BOULEVARD, Somerville, MA 02145
- EDGAR entity type
- operating
- Insiders and CEO pay
- bluebird bio, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2013-06-04)
- Final price
- $17.00 per share, above the range (424B4 filed 2013-06-19, an initial public offering)
- Shares sold
- 5,941,176
- Gross proceeds
- $100,999,992 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol BLUE
- Lead underwriters
- J.P. Morgan; Merrill Lynch (1,746,705 shares)
- Syndicate
- BofA Securities; Cowen (1,449,646); Canaccord Genuity (201,999); Wedbush Securities (201,999)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Federal award recipient: BLUEBIRD BIO, INC. Fuzzy (name and state)
- Form D issuer: bluebird bio, Inc. EXACT (CIK (EXACT))
- Lobbying client: BLUEBIRD BIO Fuzzy (name and state)
- Lobbying client: BLUEBIRD BIO Fuzzy (name and state)
- Lobbying client: BLUEBIRD BIO Fuzzy (name and state)
- Lobbying client: BLUEBIRD BIO, INC. Fuzzy (name and state)
- Lobbying registrant: BLUEBIRD BIO, INC. Fuzzy (name and state)
- SEC filer: bluebird bio, Inc. EXACT (CIK (EXACT))
- Person page: Mary Lynne Hedley Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-05-14 | S-1 | S-1 (registration) | bluebird bio, Inc. | 0001193125-13-219925 ↗ |
| 2013-05-21 | S-1/A | S-1/A (amendment) | bluebird bio, Inc. | 0001193125-13-229838 ↗ |
| 2013-06-04 | S-1/A | S-1/A (amendment) | bluebird bio, Inc. | 0001193125-13-246004 ↗ |
| 2013-06-18 | S-1MEF | S-1MEF (added securities) | bluebird bio, Inc. | 0001193125-13-262959 ↗ |
| 2013-06-18 | EFFECT | EFFECT (declared effective) | bluebird bio, Inc. | 9999999995-13-001837 ↗ |
| 2013-06-19 | 424B4 | 424B4 (final prospectus) | bluebird bio, Inc. | 0001193125-13-263506 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-06-04 | S-1/A | registration statement | $14.00–$16.00 | 5,000,000 | - | Nasdaq BLUE | 6 | primary document; range, shares headline, cover names 5 | document ↗ | |
| 2013-06-19 | 424B4 | final prospectus | $17.00 | 5,941,176 | $100,999,992 | Nasdaq BLUE | 6 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Arch Venture Fund VII LP | TenPercentOwner | 2 | 2013 | ||
| ARCH Venture Partners VII, LLC | TenPercentOwner | 2 | 2013 | ||
| ARCH Venture Partners VII, L.P. | TenPercentOwner | 2 | 2013 | ||
| Bain Linda | Officer | VP, Fin. & Business Operations | 7 | 2013–2014 | |
| Birner Hubert | TenPercentOwner | 2 | 2013 | ||
| BYBEE CLINTON | TenPercentOwner | 2 | 2013 | ||
| CRANDELL KEITH | TenPercentOwner | 2 | 2013 | ||
| Davidson David | Officer | Chief Medical Officer | 92 | 2013–2021 | |
| DIXON WENDY L | Director | 10 | 2013–2021 | ||
| Finer Mitchell H. | Officer | Chief Scientific Officer | 17 | 2013–2015 | |
| Fischer Stefan | TenPercentOwner | 2 | 2013 | ||
| GILLIS STEVEN | Director | 12 | 2013–2015 | ||
| Goll Alexandra | TenPercentOwner | 2 | 2013 | ||
| Leschly Nick | Director; Director,Officer | President and CEO | 66 | 2013–2025 | |
| LYNCH DANIEL | Director | 29 | 2013–2021 | ||
| MARAGANORE JOHN | Director | 11 | 2013–2017 | ||
| Mulder Geert-Jan | Director | 2 | 2013 | ||
| NELSEN ROBERT | TenPercentOwner | 2 | 2013 | ||
| Polack Axel | Director; TenPercentOwner | 4 | 2013 | ||
| Schenkein David P | Director | 12 | 2013–2020 | ||
| SCHUHSLER HELMUT | TenPercentOwner | 2 | 2013 | ||
| TEPPER ROBERT I | Director; Director,TenPercentOwner | 9 | 2013–2015 | ||
| Third Rock Ventures GP, L.P. | TenPercentOwner | 8 | 2013–2015 | ||
| THIRD ROCK VENTURES LP | TenPercentOwner | 8 | 2013–2015 | ||
| TRV GP, LLC | TenPercentOwner | 8 | 2013–2015 | ||
| TVM Capital GmbH | TenPercentOwner | 2 | 2013 | ||
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | TenPercentOwner | 2 | 2013 | ||
| Walsh Jeffrey T. | Officer; OfficerOther | Chief Financial; Chief Financial and; Chief Operating Officer; Chief Strategy Officer | 63 | 2013–2019 | |
| Mandell James | Director | 15 | 2014–2018 | ||
| Cole Jason | Officer; OfficerOther | Chief Business Officer; Chief Legal Officer; Chief Operating and; Chief Strategy & Financial Off; SVP, Secy. & General Counsel | 53 | 2014–2022 | |
| Sullivan Eric | Officer; OfficerOther | Principal Accounting Officer; VP, Finance & Treasurer | 29 | 2014–2017 | |
| Vachon Mark | Director | 19 | 2014–2025 | ||
| DETORE JAMES M. | Officer | Chief Financial Officer | 2 | 2014 | |
| Gregory Philip D | Officer | Chief Scientific Officer | 67 | 2015–2021 | |
| HIGH SUSANNA GATTI | Officer | Chief Operating Officer | 10 | 2016–2018 | |
| Agwunobi John O | Director | 11 | 2017–2025 | ||
| MELTON DOUGLAS | Director | 5 | 2017–2020 | ||
| Hedley Mary Lynne | Director | 3 | 2017–2018 | person page Fuzzy | |
| WENTWORTH KORY JAMES | Officer | Principal Accounting Officer | 15 | 2017–2020 | |
| FINGER ALISON CECILY | Officer | Chief Commercial Officer | 18 | 2018–2021 | |
| Baird William D III | Officer | Chief Financial Officer | 9 | 2019–2021 | |
| Sellers William R. | Director | 5 | 2019–2021 | ||
| Smith-Farrell Joanne | Officer | Chief Business Officer; COO, Oncology | 15 | 2020–2021 | |
| Torres Denice | Director | 4 | 2020–2021 | ||
| Burnett Katy | Officer | Principal Accounting Officer | 4 | 2020–2021 | |
| Ibrahim Ramy | Director | 4 | 2021 | ||
| Obenshain Andrew | Director,Officer; Officer | Chief Executive Officer; President and CEO; President of SGD | 29 | 2021–2025 | |
| Klima Thomas J | Officer | Chief Commercial Officer; Chief Commercial Officer, SGD; See Remarks | 17 | 2021–2025 | |
| Maus Marcela V. | Director | 3 | 2021 | ||
| Glickman Sarah JS | Director | 3 | 2021 | ||
| Tita-Reid Najoh | Director | 7 | 2021–2025 | ||
| Leiderman Elisabeth | Director | 8 | 2021–2025 | ||
| Consylman Gina | Officer | Chief Financial Officer | 3 | 2021–2022 | |
| Whitten Jessica | Officer | Chief Accounting Officer | 6 | 2021–2022 | |
| Eggimann Anne-Virginie | Officer | Chief Regulatory Officer | 3 | 2022 | |
| Jones-Burton Charlotte | Director | 6 | 2022–2025 | ||
| Colvin Richard A | Officer | Chief Medical Officer | 15 | 2022–2025 | |
| Krawtschuk Christopher | Officer | Chief Financial Officer | 4 | 2022–2024 | |
| Vittiglio Joseph | Officer | Chief Business & Legal Officer | 7 | 2023–2025 | |
| Paulson Richard A. | Director | 4 | 2023–2025 | ||
| Sterling O. James | Officer | Chief Financial Officer | 4 | 2024–2025 | |
| Cloonan Michael | Director | 4 | 2024–2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-09-21 | bluebird bio, Inc. | Biotechnology | $74,977,264 | $74,977,264 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Federal award recipient | BLUEBIRD BIO, INC. | MA | Federal spending (USAspending) | name and state |
| Form D issuer | bluebird bio, Inc. | MA | Form D private offerings | CIK (EXACT) |
| Lobbying client | BLUEBIRD BIO | MA | Federal lobbying (LDA) | name and state |
| Lobbying client | BLUEBIRD BIO | MA | Federal lobbying (LDA) | name and state |
| Lobbying client | BLUEBIRD BIO | MA | Federal lobbying (LDA) | name and state |
| Lobbying client | BLUEBIRD BIO, INC. | MA | Federal lobbying (LDA) | name and state |
| Lobbying registrant | BLUEBIRD BIO, INC. | MA | Federal lobbying (LDA) | name and state |
| Patent assignee | BLUEBIRD BIO, INC. | MA | Patents (USPTO) | name and state |
| SEC filer | bluebird bio, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | bluebird bio, Inc. | MA | Trademarks (USPTO) | name and state |
| Person page | Mary Lynne Hedley | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MA first:
- TRANSCEND THERAPEUTICS INC MA
- Eloxx Pharmaceuticals, Inc. MA
- PANACOS PHARMACEUTICALS, INC. MA
- CHARLES RIVER LABORATORIES INC MA
- AGENUS INC MA
- CURIS INC MA
- MOMENTA PHARMACEUTICALS INC MA
- ACCELERON PHARMA INC MA
- Altus Pharmaceuticals Inc. MA
- BioVex Group, Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health